Artificial Intelligence in Cancer Care and Clinical Trials
Arturo Loaiza-Bonilla, MD, discusses artificial intelligence in cancer care and clinical trials.
Related Articles
Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.
IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma
The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.
Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML
Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.
Dr Powles on Implications of the CREST Study of Sasanlimab Plus BCG in BCG-Naive NMIBC
Thomas Powles, MD, MBBS, MRCP, discusses the implications of data from sasanlimab plus BCG in patients with BCG-naive, high-risk NMIBC.
FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML and Hematologic Malignancies
SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.
Zanubrutinib/Venetoclax Yields Deep Responses in Treatment-Naive CLL Regardless of Del17p/TP53 Mutational Status
Mazyar Shadman, MD, MPH, discusses key efficacy and safety findings from arm D of the SEQUOIA trial of first-line zanubrutinib plus venetoclax in CLL/SLL.
Dr McArthur on the Efficacy of Pembrolizumab Plus Neoadjuvant Chemo in TNBC
Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.
Ibrutinib Plus Venetoclax and A CD20 Monoclonal Antibody Increases MRD Negativity in Untreated MCL
Treatment with ibrutinib plus venetoclax and a CD20 monoclonal antibody induced high MRD negativity rates vs ibrutinib/anti-CD20 in untreated MCL.
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.